ziyuglycoside II

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
01220132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Ziyuglycoside I (ZGS1) is a promising drug candidate for the treatment of leucopenia. Currently, information on ZGS1 and its in… (More)
Is this relevant?
Review
2018
Review
2018
Sanguisorba officinalis Linne (S. officinalis, Rosaceae) has been used as a medicinal plant for the treatment of burns… (More)
Is this relevant?
2017
2017
Ziyuglycoside II, a major bioactive compound of Sanguisorba officinalis L., displays anticancer potential against several human… (More)
Is this relevant?
2017
2017
Radix Sanguisorbae, the root of Sanguisorba officinalis L. is used as traditional Chinese medicine. In recent decades, it has… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Ziyuglycoside I is one of the major active ingredients in Sanguisorba officinalis, a popular medicinal plant in China. In the… (More)
Is this relevant?
2016
2016
Ziyuglycoside II, one of the major effective ingredients of Sanguisorba officinalis L., had various pharmacological activities… (More)
Is this relevant?
2015
2015
This study provided a novel and generally applicable method to determine ziyuglycoside I and ziyuglycoside II in rat plasma based… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2014
2014
Ziyuglycoside II, a triterpenoid saponin compound extracted from Sanguisorba officinalis L., has been reported to have a wide… (More)
Is this relevant?
2013
2013
Ziyuglycoside II is an active compound of Sanguisorba officinalis L. that has anti-inflammation, antioxidation, antibiosis, and… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Ziyuglycoside II is one of the major active compounds of Sanguisorba officinalis L., which has a wide range of clinical… (More)
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?